Former U.S. President Donald Trump’s new tariff policies could cause serious problems for Indian pharmaceutical companies. The increased import tariffs in the United States will raise production costs for Indian manufacturers, making it harder to compete with other countries.
Impact on Small Pharma Companies
🔹 Small Indian pharma companies, which already work on low profit margins, will face extreme pressure.
🔹 Some companies may merge with others or even shut down their businesses.
🔹 The automobile sector will not be affected much because the U.S. is a small export market for Indian vehicles.
Trump’s Tariff Policy
👉 Trump has announced new tariffs starting from April 2.
👉 He said that countries imposing tariffs on American goods will face higher tariffs in return.
👉 Currently, India charges a 10% import tax on American medicines, while the U.S. does not charge any import tax on Indian medicines.
How Will This Impact India’s Pharma Sector?
According to Arvind Sharma, a partner at Shardul Amarchand Mangaldas & Co:
✅ The U.S. is a major importer of medicines to meet its domestic demand.
✅ If heavy tariffs are imposed on Indian medicines, it will affect Indian pharma companies and also disrupt medicine supply in the U.S.
India’s Role in the U.S. Pharma Market
📌 In 2022, Indian companies supplied 40% of all prescribed medicines in the U.S.
📌 Indian medicines helped save $219 billion in U.S. healthcare costs in 2022 alone.
📌 Between 2013 and 2022, Indian medicines saved the U.S. $1.3 trillion.
📌 In the next five years, Indian generic drugs could save an additional $1.3 trillion.
Sharma also said:
👉 India’s pharma industry depends heavily on the U.S., which accounts for one-third of India’s total medicine exports.
👉 If tariffs increase, U.S. healthcare costs will rise, putting more financial burden on American consumers.
👉 This may limit access to affordable medicines in the U.S.
Effect on the Automobile Sector
📌 Shashi Mathews, a partner at IndusLaw, said that Trump’s new policies will have minimal effect on India’s automobile industry.
📌 The Indian auto sector is not heavily dependent on U.S. exports, so counter-tariffs from the U.S. will not impact it significantly.
Conclusion
Trump’s tariff war is set to increase medicine costs in both India and the U.S.. While Indian pharma companies will struggle with higher costs and competition, U.S. consumers will face more expensive healthcare. Meanwhile, the Indian automobile sector is expected to remain mostly unaffected. 🚗💊💰


